OncoSil Medical (ASX:OSL) has secured TGA approval for its OncoSil device, opening the Australian pancreatic cancer market for the first time.
Healthcare Stocks
4DMedical (ASX:4DX) published peer-reviewed CT VQ data in AJRCCM showing lung surgery success rates lift from 46% to 76% via better patient selection.
Pro Medicus Wins A$90m Beth Israel Lahey Deal
Pro Medicus (ASX:PME) has landed another major US contract, signing a seven-year, A$90m deal with Beth Israel Lahey Health, a Boston-based hospital network. The contract will see Pro Medicus roll out its cloud-based Visage 7 imaging platform across 14 hospitals in Massachusetts and New Hampshire, with the…
Racura Oncology Surges on Trial Update
Racura Oncology (ASX: RAC) climbed 8.66 per cent on Friday to close at A$2.76, after the independent Safety Review Committee cleared the company to double the dosage level in its CPACS Phase 1 cancer trial. The first three patients in Cohort 1 showed no dose-limiting toxicities and remain alive…
Osteopore (ASX:OSX) secured Malaysian regulatory access for its orthopaedic portfolio, opening a US$250-300m bone graft market with a halal-friendly biomaterials angle.
AVITA Medical (ASX:AVH) Q1 2026 revenue rose 10% sequentially to US$19.3m but cash fell to US$14.3m as a new CEO and BARDA deal reset the story.
It is hard to look back on something and say it failed especially if it was a US$11.7bn bet as CSL's Vifor acquisition was. But what else can you say? Impairments now total roughly US$6.5bn, the share price is barely over $100 having peaked at over $300 only a couple of years ago and the…
CSL Hits Decade Lows: Buy the Dip or Wait?
CSL (ASX:CSL) shares slipped another 2% today, extending yesterday's brutal sell-off that pushed the stock to its lowest level since 2017. The biotech heavyweight is now down around 44% for the year, a fall few investors would have thought possible for what was long considered one…
BPH Global (ASX:BP8) has signed a Singapore Polytechnic FIRC agreement to develop powdered seaweed kefir, signalling a pivot to a functional ingredients model.
dorsaVi (ASX:DVL) has renewed its US DoD-funded research contract with Georgia Southern University, framing the study as a proving ground for exoskeletons.
